<DOC>
	<DOCNO>NCT02497248</DOCNO>
	<brief_summary>Currently available antiarrhythmic drug treatment atrial fibrillation ( AF ) limit efficacy often cause long-term side effect . Pulmonary vein isolation therapy choice drug-refractory patient . Recent study show ablation great efficacy patient AF maintain hierarchically ablation rotor . The non-invasive identification specific mechanism AF maintenance patient could allow selection appropriate treatment .</brief_summary>
	<brief_title>Non-invasive Characterization Mechanisms Atrial Fibrillation Maintenance</brief_title>
	<detailed_description>The MAIN GOAL project clinically validate technology noninvasive identification mechanism responsible maintenance AF body surface electrical mapping . To achieve goal , noninvasive map atrial activity correlate simultaneous endocardial mapping ( high density contact catheter ) use advanced signal analysis technique ( Dominant frequency , phase causality mapping , inverse solution problem ) . These analysis perform patient different mechanism maintenance AF ( e.g . paroxysmal , persistent , valvular ) undergo AF ablation clinical indication . Both endocardial body surface map result correlate biomarkers level , MRI scan AF outcome AF ablation 6 month 1 year procedure . Wide antrum circumferential pulmonary vein isolation demonstration bidirectional block perform use standard cooled-tip radiofrequency catheter . In patient mitral stenosis , PBMV perform accord Inoue´s technique follow wide antrum circumferential pulmonary vein isolation . In patient , MRI/CT scan fibrosis biomarkers obtain baseline , 6 month 1 year post ablation .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patients paroxysmal AF symptomatic refractory least one antiarrhythmic medication . Patients persistent AF symptomatic refractory least one antiarrhythmic medication . Patients severe mitral stenosis ( mitral valve area ≤1.5 cm2 , stage D ) favorable valve morphology absence leave atrial thrombus moderatetosevere mitral regurgitation . Patients must able willing provide write informed consent participate study . Prior anticoagulation &gt; 4 week transesophageal echocardiogram exclude intracardiac thrombus ( patient paroxysmal AF ) . Patients inadequate anticoagulation level . Patients leave atrial thrombus , tumor , another abnormality preclude catheter introduction TEE prior procedure . Patients moderatetosevere mitral regurgitation . Patients contraindication systemic anticoagulation heparin coumadin . Prior atrial fibrillation ablation . Patients may potentially pregnant . Contraindication adenosine administration ; Current enrollment another investigational drug device study . Pacemaker Implantable Cardioverter Defibrillator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Pulmonary Vein Ablation</keyword>
	<keyword>Mitral stenosis</keyword>
	<keyword>Body surface mapping</keyword>
</DOC>